N
Nora D. Volkow
Researcher at National Institute on Drug Abuse
Publications - 1038
Citations - 121498
Nora D. Volkow is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine & Addiction. The author has an hindex of 165, co-authored 958 publications receiving 107463 citations. Previous affiliations of Nora D. Volkow include National Institutes of Health & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Intentional Drug Overdose Deaths in the United States.
Beth Han,Wilson M. Compton,Emily B Einstein,Jessica H Cotto,Jennifer A. Hobin,Jack B. Stein,Nora D. Volkow +6 more
TL;DR: Han et al. as mentioned in this paper examined the differences in national trends in intentional drug overdose deaths by age, race/ethnicity, and sex, compared with firearm deaths by suicide, and found that suicide rates increased with age.
Journal ArticleDOI
Spatial and temporal distribution of cocaine and effects of pharmacological interventions: wholebody autoradiographic microimaging studies.
Peter M. Som,Z. H. Oster,Z. H. Oster,Gene-Jack Wang,Gene-Jack Wang,Nora D. Volkow,Nora D. Volkow,D.F. Sacker +7 more
TL;DR: Whole body timed distribution of pharmacological doses of 14C-cocaine was studied in rats using quantitative autoradiographic microimaging and the targeting of cocaine to specific organs and the time sequence correspond to the pharmacological effects of cocaine.
Journal ArticleDOI
Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses.
Mengshi Zhou,Mengshi Zhou,QuanQiu Wang,Chunlei Zheng,A. John Rush,A. John Rush,A. John Rush,Nora D. Volkow,Rong Xu +8 more
TL;DR: In this paper, an integrated drug repurposing strategy that combines computational prediction, clinical corroboration using electronic health records (EHRs) of over 72.9 million patients and mechanisms of action analysis was presented.
Journal ArticleDOI
Emergency Department Visits From Edible Versus Inhalable Cannabis.
Nora D. Volkow,Ruben Baler +1 more
TL;DR: The higher-than-expected number of adverse events associated with edible cannabis products, considering their market share relative to inhalable products, is consistent with prior findings.